Science

Petros Grivas/fredhutch.org

Dec 24, 2024, 07:56

Petros Grivas: Excited to see long term follow up of our IMvigor210 trial

Petros Grivas, Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance, shared an article by on X:

“Excited to see long term follow up of our IMvigor210 trial in bladder cancer.

Jonathan Rosenberg, Matt Galsky, Joaquim Bellmunt, Jean Hoffman-Censits, Michiel van der Heijden, K. Sridhar, Y. Loriot, Andrea Necchi, Daniel Castellano, et al.”

Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial.

Authors: J.E. Rosenberg, et al.

Petros Grivas: Excited to see long term follow up of our IMvigor210 trial

Dr. Petros Grivas, a board-certified medical oncologist, serves as Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance. He’s an Associate Professor at the Dept. of Medicine and Associate Member at Fred Hutchinson Cancer Research Center since January 2018. With extensive training and experience, he’s led clinical trials, contributing to FDA approvals for bladder/urothelial cancer treatments.

Andrea Necchi atezolizumab bladder cancer cancer Daniel Castellano fight against cancer Genitourinary Cancers Program IMvigor210 J.E. Rosenberg Jean Hoffman-Censits Joaquim Bellmunt Jonathan Rosenberg K. Sridhar KSridhar Matt Galsky Michiel van der Heijden OncoDaily Oncology Petros Grivas University of Washington Y. Loriot

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Writer?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen

Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...